Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Hay

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of Acquired Immune Deficiency Syndromes|January 1, 1988
Projecting the medical costs of AIDS and ARC in the United StatesJ W Hay, D H Osmond, M A Jacobson
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 12, 1999
Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia AJ W Hay, R L Ernst, C M Kessler
The American Journal of Cardiology|April 25, 1991
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reductionJ W Hay, E H Wittels, A M Gotto
The American Journal of Cardiology|February 15, 1990
Medical costs of coronary artery disease in the United StatesE H Wittels, J W Hay, A M Gotto
Health Care Financing Review|December 7, 1983
Physician pricing and health insurance reimbursementD E Yett, W Der, R L Ernst, et al.
Health Care Financing Review|January 6, 1982
Blue Shield plan physician participationD E Yett, W Der, R L Ernst, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 6, 2006
Commentary on Langley and McKenney PapersT Ashraf, P C Langley, J W Hay, et al.
Archives of Neurology|June 1, 1997
Cognitive function and the costs of Alzheimer disease. An exploratory studyR L Ernst, J W Hay, C Fenn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 6, 2006
From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forumP C Langley, J W Hay, J S Schwartz, et al.
Clinical Drug Investigation|May 18, 2007
Economic burden of haematological adverse effects in cancer patients: a systematic reviewS Y Liou, J M Stephens, K T Carpiuc, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Acquired Immune Deficiency Syndromes|January 1, 1988
Projecting the medical costs of AIDS and ARC in the United StatesJ W Hay, D H Osmond, M A Jacobson
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 12, 1999
Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia AJ W Hay, R L Ernst, C M Kessler
The American Journal of Cardiology|April 25, 1991
An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reductionJ W Hay, E H Wittels, A M Gotto
The American Journal of Cardiology|February 15, 1990
Medical costs of coronary artery disease in the United StatesE H Wittels, J W Hay, A M Gotto
Health Care Financing Review|December 7, 1983
Physician pricing and health insurance reimbursementD E Yett, W Der, R L Ernst, et al.
Health Care Financing Review|January 6, 1982
Blue Shield plan physician participationD E Yett, W Der, R L Ernst, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 6, 2006
Commentary on Langley and McKenney PapersT Ashraf, P C Langley, J W Hay, et al.
Archives of Neurology|June 1, 1997
Cognitive function and the costs of Alzheimer disease. An exploratory studyR L Ernst, J W Hay, C Fenn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 6, 2006
From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forumP C Langley, J W Hay, J S Schwartz, et al.
Clinical Drug Investigation|May 18, 2007
Economic burden of haematological adverse effects in cancer patients: a systematic reviewS Y Liou, J M Stephens, K T Carpiuc, et al.
Pageof 5